Abstract
Background: Ustekinumab (UST), an antibody targeting the p40 subunit of interleukin (IL)-12 and IL-23, is effective in treating Crohn’s disease (CD). To clarify the mechanism of UST, we investigated T-cell differentiation in CD patients treated with UST. Methods: Twenty-seven patients with active CD were enrolled in this study. Seventeen patients were treated with UST, and 10 patients were treated with anti-tumor necrosis factor (TNF)-alpha therapy. The changes in the proportions of T-cell subsets after these therapies were analyzed by flow cytometry. Comprehensive gene expression changes in the colonic mucosa were also evaluated. Results: The frequency of T helper (Th) 17 cells was significantly decreased in the peripheral blood of patients with active CD after UST therapy. Anti-TNF therapy had a minimal effect on Th17 cells but increased the proportion of regulatory T cells. Enrichment analysis showed the expression of genes involved in the Th17 differentiation pathway was downregulated in the colonic mucosa after UST but not anti-TNF therapy. There were no common differentially expressed genes between CD patients treated with UST and anti-TNF therapy, suggesting a clear difference in their mechanism of action. Conclusion: In patients with active CD, UST therapy suppressed Th17 cell differentiation both in the peripheral blood and colonic tissues.
Journal Section:
Research Article
References
1.
Abraham
C
, Dulai
PS
, Vermeire
S
, Sandborn
WJ
. Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases
. Gastroenterology
. 2017 Feb
;152
(2
):374
–e4
.2.
Giuffrida
P
, Corazza
GR
, Di Sabatino
A
. Old and new lymphocyte players in inflammatory bowel disease
. Dig Dis Sci
. 2018 Feb
;63
(2
):277
–88
.3.
Brand
S
. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease
. Gut
. 2009 Aug
;58
(8
):1152
–67
.4.
Volpe
E
, Servant
N
, Zollinger
R
, Bogiatzi
SI
, Hupé
P
, Barillot
E
, . A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses
. Nat Immunol
. 2008 Jun
;9
(6
):650
–7
.5.
Kamada
N
, Hisamatsu
T
, Okamoto
S
, Chinen
H
, Kobayashi
T
, Sato
T
, . Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis
. J Clin Invest
. 2008 Jun
;118
(6
):2269
–80
.6.
Duerr
RH
, Taylor
KD
, Brant
SR
, Rioux
JD
, Silverberg
MS
, Daly
MJ
, . A genome-wide association study identifies IL23R as an inflammatory bowel disease gene
. Science
. 2006 Dec 1
;314
(5804
):1461
–3
.7.
Uniken Venema
WT
, Voskuil
MD
, Vila
AV
, van der Vries
G
, Jansen
BH
, Jabri
B
, . Single-cell RNA sequencing of blood and ileal T cells from patients with crohn's disease reveals tissue-specific characteristics and drug targets
. Gastroenterology
. 2019 Feb
;156
(3
):812
–e22
.8.
Feagan
BG
, Sandborn
WJ
, Gasink
C
, Jacobstein
D
, Lang
Y
, Friedman
JR
, . Ustekinumab as induction and maintenance therapy for Crohn’s disease
. N Engl J Med
. 2016 Nov 17
;375
(20
):1946
–60
.9.
Targan
SR
, Hanauer
SB
, van Deventer
SJ
, Mayer
L
, Present
DH
, Braakman
T
, . A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 study group
. N Engl J Med
. 1997 Oct 9
;337
(15
):1029
–35
.10.
Benson
JM
, Sachs
CW
, Treacy
G
, Zhou
H
, Pendley
CE
, Brodmerkel
CM
, . Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab
. Nat Biotechnol
. 2011 Jul
;29
(7
):615
–24
.11.
Sandborn
WJ
, Feagan
BG
, Hanauer
SB
, Lochs
H
, Löfberg
R
, Modigliani
R
, . A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease
. Gastroenterology
. 2002 Feb
;122
(2
):512
–30
.12.
Verstockt
B
, Dreesen
E
, Noman
M
, Outtier
A
, Van den Berghe
N
, Aerden
I
, . Ustekinumab exposure-outcome analysis in Crohn’s disease only in part explains limited endoscopic remission rates
. J Crohns Colitis
. 2019 Jul 25
;13
(7
):864
–72
.13.
Schmitt
H
, Billmeier
U
, Dieterich
W
, Rath
T
, Sonnewald
S
, Reid
S
, . Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease
. Gut
. 2019 May
;68
(5
):814
–28
.14.
Sugio
T
, Miyawaki
K
, Kato
K
, Sasaki
K
, Yamada
K
, Iqbal
J
, . Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS
. Blood Adv
. 2018 Sep 11
;2
(17
):2242
–52
.15.
Zhou
Y
, Zhou
B
, Pache
L
, Chang
M
, Khodabakhshi
AH
, Tanaseichuk
O
, . Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
. Nat Commun
. 2019 Apr 3
;10
(1
):1523
.16.
Bsat
M
, Chapuy
L
, Rubio
M
, Wassef
R
, Richard
C
, Schwenter
F
, . Differential pathogenic Th17 profile in mesenteric lymph nodes of Crohn’s disease and ulcerative colitis patients
. Front Immunol
. 2019
;10
:1177
.17.
Sakuraba
A
, Sato
T
, Kamada
N
, Kitazume
M
, Sugita
A
, Hibi
T
. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn’s disease
. Gastroenterology
. 2009 Nov
;137
(5
):1736
–45
.18.
Di Sabatino
A
, Biancheri
P
, Piconese
S
, Rosado
MM
, Ardizzone
S
, Rovedatti
L
, . Peripheral regulatory T cells and serum transforming growth factor-beta: relationship with clinical response to infliximab in Crohn’s disease
. Inflamm Bowel Dis
. 2010 Nov
;16
(11
):1891
–7
.19.
Chiba
T
, Endo
M
, Miura
S
, Hayashi
Y
, Asakura
Y
, Oyama
K
, . Regulatory T cells in Crohn’s disease following anti-TNF-α therapy
. JGH Open
. 2020 Jun
;4
(3
):378
–81
.20.
Mitoma
H
, Horiuchi
T
, Tsukamoto
H
, Tamimoto
Y
, Kimoto
Y
, Uchino
A
, . Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab
. Arthritis Rheum
. 2008 May
;58
(5
):1248
–57
.21.
Globig
AM
, Sommer
NP
, Wild
K
, Schardey
J
, Zoldan
K
, Thomann
AK
, . Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
. Cell Mol Gastroenterol Hepatol
. 2021
;11
(1
):1
–12
.22.
Nagata
Y
, Esaki
M
, Moriyama
T
, Hirano
A
, Umeno
J
, Maehata
Y
, . Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn’s disease of inflammatory type
. J Gastroenterol
. 2019 Apr
;54
(4
):330
–8
.23.
Schnitzler
F
, Fidder
H
, Ferrante
M
, Noman
M
, Arijs
I
, Van Assche
G
, . Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort
. Gut
. 2009 Apr
;58
(4
):492
–500
.24.
Rudolph
SJ
, Weinberg
DI
, McCabe
RP
. Long-term durability of Crohn’s disease treatment with infliximab
. Dig Dis Sci
. 2008 Apr
;53
(4
):1033
–41
.25.
Miyagawa
I
, Nakayamada
S
, Nakano
K
, Kubo
S
, Iwata
S
, Miyazaki
Y
, . Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis
. Rheumatology
. 2019 Feb 1
;58
(2
):336
–44
.© 2021 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2021
You do not currently have access to this content.
